Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Suspends GSK Tender Qualification Under Dutasteride Ban

Executive Summary

GSK becomes the second foreign pharma firm in recent months to be hit with a ban on the import, sale and use of a product by increasingly assertive Chinese regulatory authorities.

You may also be interested in...



China 'No' For Celgene's Paclitaxel A Major Blow To BeiGene

After winning a major procurement contract, BeiGene now may need to find an alternative manufacturing site for  Celgene's Abraxane to supply China.

Behind A Rekindled Dream And China Biotech’s New Reality

The latest mega deals aimed at bringing Chinese innovation to the US have rekindled go-global hopes for a sector badly needing some cheer. But some investors say out-licensing may be the best route and that Chinese biotech must scale back its do-all mentality and focus on what it does best amid a new reality.

Paradox Of China Biotech And What Lies Ahead In 2023

The hard going could get even tougher as a funding crunch continues for China’s biotech sector, which is being hit by a paradox that could see more pain ahead, leading investors to take the pulse of the sector as the Year of the Rabbit starts.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147267

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel